Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein-Barr Virus Infection in University Students

Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveil...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 207; no. 1; pp. 80 - 88
Main Authors Balfour, Henry H., Odumade, Oludare A., Schmeling, David O., Mullan, Beth D., Ed, Julie A., Knight, Jennifer A., Vezina, Heather E., Thomas, William, Hogquist, Kristin A.
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 01.01.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (< .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8⁺ T-cells but not in numbers of CD4⁺ T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8⁺ lymphocytosis (P = .0003). Conclusions. Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8⁺ lymphocytosis correlated with disease severity.
AbstractList Background.  University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein–Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods.  EBV antibody–negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results.  Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing ( P  < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8 + T-cells but not in numbers of CD4 + T-cells during acute infection. Severity of illness correlated positively with both blood EBV load ( P  = .015) and CD8 + lymphocytosis ( P  = .0003). Conclusions.  Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8 + lymphocytosis correlated with disease severity.
Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (< .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8⁺ T-cells but not in numbers of CD4⁺ T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8⁺ lymphocytosis (P = .0003). Conclusions. Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8⁺ lymphocytosis correlated with disease severity.
University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity.BACKGROUNDUniversity students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity.EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay.METHODSEBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay.Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003).RESULTSOf 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003).Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.CONCLUSIONSKissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.
University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8(+) T-cells but not in numbers of CD4(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8(+) lymphocytosis (P = .0003). Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8(+) lymphocytosis correlated with disease severity.
Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and the virologic and immune correlates of disease severity. Methods. EBV antibody-negative freshmen participated in monthly surveillance until graduation. If antibodies developed, proximate samples were assayed for viral load by polymerase chain reaction. Lymphocyte and natural killer (NK) cell numbers and activation were measured by flow cytometry, and plasma cytokine levels were measured by a multiplex assay. Results. Of 546 students screened, 202 (37%) were antibody negative; 143 antibody-negative students were enrolled. During a median of 3 years of observation, 66 subjects experienced primary infection. Of these, 77% had infectious mononucleosis, 12% had atypical symptoms, and 11% were asymptomatic. Subjects reporting deep kissing with or without coitus had the same higher risk of infection than those reporting no kissing (P < .01). Viremia was transient, but median oral shedding was 175 days. Increases were observed in numbers of NK cells and CD8 super(+) T-cells but not in numbers of CD4 super(+) T-cells during acute infection. Severity of illness correlated positively with both blood EBV load (P = .015) and CD8 super(+) lymphocytosis (P = .0003). Conclusions. Kissing was a significant risk for primary EBV infection. A total of 89% of infections were symptomatic, and blood viral load and CD8 super(+) lymphocytosis correlated with disease severity.
Author Mullan, Beth D.
Thomas, William
Balfour, Henry H.
Hogquist, Kristin A.
Ed, Julie A.
Knight, Jennifer A.
Vezina, Heather E.
Schmeling, David O.
Odumade, Oludare A.
AuthorAffiliation 4 Division of Biostatistics, School of Public Health , University of Minnesota Medical School , Minneapolis
1 Department of Laboratory Medicine and Pathology
3 Department of Experimental and Clinical Pharmacology
2 Department of Pediatrics
AuthorAffiliation_xml – name: 2 Department of Pediatrics
– name: 4 Division of Biostatistics, School of Public Health , University of Minnesota Medical School , Minneapolis
– name: 1 Department of Laboratory Medicine and Pathology
– name: 3 Department of Experimental and Clinical Pharmacology
Author_xml – sequence: 1
  givenname: Henry H.
  surname: Balfour
  fullname: Balfour, Henry H.
– sequence: 2
  givenname: Oludare A.
  surname: Odumade
  fullname: Odumade, Oludare A.
– sequence: 3
  givenname: David O.
  surname: Schmeling
  fullname: Schmeling, David O.
– sequence: 4
  givenname: Beth D.
  surname: Mullan
  fullname: Mullan, Beth D.
– sequence: 5
  givenname: Julie A.
  surname: Ed
  fullname: Ed, Julie A.
– sequence: 6
  givenname: Jennifer A.
  surname: Knight
  fullname: Knight, Jennifer A.
– sequence: 7
  givenname: Heather E.
  surname: Vezina
  fullname: Vezina, Heather E.
– sequence: 8
  givenname: William
  surname: Thomas
  fullname: Thomas, William
– sequence: 9
  givenname: Kristin A.
  surname: Hogquist
  fullname: Hogquist, Kristin A.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27110422$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/23100562$$D View this record in MEDLINE/PubMed
BookMark eNqFkktr3DAUhUVJaSZpl122aFPoIm70sCV7U5iEJB0ItJCmXRpZljJ38EgTSR7IH-nvjR1Ppw8oXQmk79x7ru45QgfOO4PQa0o-UFLxU3C2hXi6gihy8QzNaMFlJgTlB2hGCGMZLavqEB3FuCKE5FzIF-iQcUpIIdgM_TgzS7UFH1R3gr9B8J2_A32ClWvxYr3u3XSBL5VOPkQ8j9FrUMm0-DukJZ7r-x4iJPDuSXNjtiZAesDe4i8B1io84ItNTAZcdqZCGHv0ES-cNfpJBA7fOhhEcVTdpL41LsWX6LlVXTSvducxur28-Hr-Kbv-fLU4n19nOpcsZbZgSjBaClLmBa9IXuaEyqJsLLes0Yo0zDAliS0JbRtCc1lSXbW8og2XrRX8GH2c6m76Zm1aPfQefqLeTM5rr6D-88XBsr7z25oXjMtKDgXe7woEf9-bmOo1RG26Tjnj-1hTkTPBCiGK_6NMciZZWVYD-vZ3W3s_P_c2AO92gIpadTYopyH-4iSlJGcjl02cDj7GYOweoaQe81NP-amn_Aw8_4vXkNS4qGF66P6pejOpVnEIyb5FTiUTVFT8EZ1V2CE
CODEN JIDIAQ
CitedBy_id crossref_primary_10_3390_vaccines9111290
crossref_primary_10_1111_bjh_14339
crossref_primary_10_1111_apt_14933
crossref_primary_10_1016_j_smim_2022_101652
crossref_primary_10_1080_07448481_2020_1726927
crossref_primary_10_1038_s41598_020_70129_4
crossref_primary_10_1093_cid_ciy464
crossref_primary_10_1016_j_celrep_2013_11_041
crossref_primary_10_1136_bcr_2022_250081
crossref_primary_10_1007_s40588_019_00120_9
crossref_primary_10_1016_j_vaccine_2016_04_012
crossref_primary_10_1128_JVI_00382_17
crossref_primary_10_3390_v14122709
crossref_primary_10_3390_ijerph18084080
crossref_primary_10_7759_cureus_29784
crossref_primary_10_1016_j_vaccine_2015_10_024
crossref_primary_10_1016_j_cell_2022_08_026
crossref_primary_10_1371_journal_ppat_1005549
crossref_primary_10_3390_cells11172757
crossref_primary_10_3389_fonc_2020_01723
crossref_primary_10_46310_tjim_1303184
crossref_primary_10_22625_2072_6732_2020_12_4_93_100
crossref_primary_10_1093_cid_ciu206
crossref_primary_10_1099_jmm_0_000616
crossref_primary_10_1128_JVI_01466_17
crossref_primary_10_26565_2313_6693_2021_43_08
crossref_primary_10_1080_15321819_2019_1705483
crossref_primary_10_1002_14651858_CD011487_pub2
crossref_primary_10_1093_cid_ciu204
crossref_primary_10_1093_infdis_jiv340
crossref_primary_10_3389_fimmu_2021_640918
crossref_primary_10_3389_fimmu_2020_581419
crossref_primary_10_1016_j_jemermed_2018_01_031
crossref_primary_10_3389_fimmu_2016_00323
crossref_primary_10_1371_journal_ppat_1008477
crossref_primary_10_1128_CVI_00674_15
crossref_primary_10_1016_j_jpag_2020_06_018
crossref_primary_10_1182_blood_2014_01_553024
crossref_primary_10_1093_protein_gzab034
crossref_primary_10_1016_j_trre_2016_12_001
crossref_primary_10_3923_biotech_2022_110_119
crossref_primary_10_1016_j_jiph_2015_06_011
crossref_primary_10_1055_a_1822_4067
crossref_primary_10_1007_s12250_018_0028_z
crossref_primary_10_1016_j_coviro_2016_08_010
crossref_primary_10_1038_cti_2016_48
crossref_primary_10_1002_eji_202048655
crossref_primary_10_3390_pathogens11070809
crossref_primary_10_1016_j_coviro_2015_08_002
crossref_primary_10_3390_microorganisms9112191
crossref_primary_10_1016_j_msard_2021_103288
crossref_primary_10_1016_j_vaccine_2012_09_041
crossref_primary_10_3390_vaccines9060655
crossref_primary_10_33667_2078_5631_2019_3_32_407__24_28
crossref_primary_10_1128_JVI_01932_15
crossref_primary_10_1186_s13052_023_01498_5
crossref_primary_10_1093_cid_ciu342
crossref_primary_10_7189_jogh_10_010404
crossref_primary_10_1093_ije_dyu118
crossref_primary_10_1099_vir_0_066712_0
crossref_primary_10_4236_aim_2020_103005
crossref_primary_10_1093_infdis_jiv114
crossref_primary_10_1007_s12098_020_03319_7
crossref_primary_10_1016_j_bmhimx_2015_12_001
crossref_primary_10_1093_infdis_jis647
crossref_primary_10_7180_kmj_2018_33_3_347
crossref_primary_10_1016_j_coviro_2015_08_014
crossref_primary_10_1111_ane_12294
crossref_primary_10_1016_j_exer_2021_108483
crossref_primary_10_1099_jgv_0_000332
crossref_primary_10_15789_2220_7619_MCO_1481
crossref_primary_10_3389_fimmu_2019_00146
crossref_primary_10_1111_jicd_12278
crossref_primary_10_1371_journal_pone_0212027
crossref_primary_10_3343_alm_2018_38_5_458
crossref_primary_10_1038_s41598_017_18195_z
crossref_primary_10_1038_s41598_020_76344_3
crossref_primary_10_4049_jimmunol_1401811
crossref_primary_10_3390_v8040105
crossref_primary_10_1038_cti_2016_28
crossref_primary_10_31586_Microbiology_0403_02
crossref_primary_10_1371_journal_ppat_1011970
crossref_primary_10_1186_s12876_019_1021_1
crossref_primary_10_1080_1744666X_2021_1847642
crossref_primary_10_1016_S2444_3409_16_30017_6
crossref_primary_10_1016_j_imbio_2020_151907
crossref_primary_10_1038_nature17655
crossref_primary_10_1016_j_jviromet_2017_02_016
crossref_primary_10_1016_j_amsu_2018_10_010
crossref_primary_10_1016_j_cpha_2016_12_010
crossref_primary_10_1016_j_diagmicrobio_2020_115295
crossref_primary_10_1016_j_jcv_2022_105267
crossref_primary_10_1016_j_cmi_2015_07_015
crossref_primary_10_1084_jem_20161846
crossref_primary_10_1111_apa_14728
crossref_primary_10_1038_s41467_019_11878_3
crossref_primary_10_1093_infdis_jit096
crossref_primary_10_1016_j_crad_2020_05_011
crossref_primary_10_11603_1681_2727_2019_3_10633
crossref_primary_10_1172_jci_insight_85687
crossref_primary_10_1111_prd_12273
crossref_primary_10_1016_j_meegid_2023_105443
crossref_primary_10_1186_s12887_022_03770_9
crossref_primary_10_3389_fonc_2018_00211
crossref_primary_10_3390_v16030463
crossref_primary_10_1177_1352458513505693
crossref_primary_10_12688_f1000research_11197_1
crossref_primary_10_3390_v8020051
crossref_primary_10_1371_journal_ppat_1005286
crossref_primary_10_3389_fimmu_2017_00197
crossref_primary_10_29413_ABS_2021_6_4_15
crossref_primary_10_1016_j_vetmic_2015_06_002
crossref_primary_10_1371_journal_ppat_1004746
crossref_primary_10_1309_LM9OWRF64OGQODEA
crossref_primary_10_1371_journal_pone_0311130
crossref_primary_10_3389_fimmu_2023_1271236
crossref_primary_10_1016_S2352_4642_21_00198_X
crossref_primary_10_1093_femsre_fuy044
crossref_primary_10_1136_jnnp_2020_322941
crossref_primary_10_4049_jimmunol_1303211
crossref_primary_10_17116_otorino20218604179
crossref_primary_10_1371_journal_ppat_1010738
crossref_primary_10_1111_nyas_12937
crossref_primary_10_1016_j_epsc_2020_101680
crossref_primary_10_1189_jlb_0313173
crossref_primary_10_1098_rstb_2018_0296
crossref_primary_10_1016_j_jneuroim_2024_578343
crossref_primary_10_1371_journal_pone_0175574
crossref_primary_10_1093_jpids_piu076
crossref_primary_10_1038_s41390_019_0591_5
crossref_primary_10_1371_journal_pone_0085422
crossref_primary_10_1016_j_med_2018_04_020
crossref_primary_10_3389_fonc_2019_00104
crossref_primary_10_1002_iid3_666
crossref_primary_10_1186_1471_2334_14_417
crossref_primary_10_1007_s40472_016_0102_0
crossref_primary_10_1128_mBio_01841_17
crossref_primary_10_4049_jimmunol_1301046
crossref_primary_10_1371_journal_pone_0115836
crossref_primary_10_1016_j_it_2014_01_003
crossref_primary_10_1111_petr_14471
crossref_primary_10_1016_j_diagmicrobio_2014_03_022
crossref_primary_10_1186_s12985_015_0441_y
crossref_primary_10_1146_annurev_immunol_032414_112326
crossref_primary_10_1097_TP_0000000000003130
crossref_primary_10_1186_s13052_023_01457_0
crossref_primary_10_3390_vaccines10091399
crossref_primary_10_1111_pin_13469
crossref_primary_10_1249_JSR_0000000000000887
crossref_primary_10_1371_journal_pntd_0005815
crossref_primary_10_1128_JVI_01293_15
crossref_primary_10_3389_fimmu_2021_757302
crossref_primary_10_1097_01_NPR_0000469261_28614_88
crossref_primary_10_1111_ijd_14887
crossref_primary_10_1080_14760584_2017_1293529
crossref_primary_10_1097_TP_0000000000001767
crossref_primary_10_1017_S0950268819000335
crossref_primary_10_3390_microorganisms7120686
crossref_primary_10_1038_cti_2014_27
crossref_primary_10_1212_NXI_0000000000200332
crossref_primary_10_1093_infdis_jit321
crossref_primary_10_1111_tid_13010
crossref_primary_10_1016_j_coviro_2014_02_005
crossref_primary_10_1111_ijcp_14690
crossref_primary_10_3389_fimmu_2016_00607
crossref_primary_10_1371_journal_pone_0226436
crossref_primary_10_1016_j_jpeds_2021_07_009
crossref_primary_10_1038_s41582_023_00775_5
crossref_primary_10_1007_s00415_017_8656_z
crossref_primary_10_1360_SSV_2024_0187
crossref_primary_10_1360_SSV_2024_0186
crossref_primary_10_2217_bmm_2020_0456
crossref_primary_10_3389_fimmu_2022_1028972
crossref_primary_10_29254_2077_4214_2021_3_161_220_224
crossref_primary_10_3390_v16010124
crossref_primary_10_1002_cti2_1451
crossref_primary_10_1182_blood_2013_11_538686
crossref_primary_10_3390_cancers15061914
crossref_primary_10_1016_j_jcv_2014_05_019
crossref_primary_10_1371_journal_ppat_1010137
crossref_primary_10_1371_journal_pone_0135512
crossref_primary_10_1186_s12985_017_0859_5
crossref_primary_10_1016_j_msard_2022_103678
crossref_primary_10_1016_j_semnephrol_2016_05_013
crossref_primary_10_1097_INF_0000000000002484
crossref_primary_10_1111_bjh_19255
crossref_primary_10_29254_2077_4214_2021_4_162_159_164
crossref_primary_10_1371_journal_pone_0261665
crossref_primary_10_3389_fimmu_2021_677027
crossref_primary_10_1007_s00431_021_04345_z
crossref_primary_10_1128_JVI_02885_13
crossref_primary_10_3389_fmicb_2017_02666
crossref_primary_10_1172_JCI86923
crossref_primary_10_1016_j_cyto_2020_155395
crossref_primary_10_3389_fimmu_2019_02193
crossref_primary_10_1186_s12967_015_0415_2
crossref_primary_10_3389_fimmu_2020_00267
crossref_primary_10_3389_fepid_2025_1518559
crossref_primary_10_1007_s13665_020_00245_z
crossref_primary_10_1080_14760584_2019_1605906
crossref_primary_10_37436_2308_5274_2020_3_15
crossref_primary_10_1016_j_jcv_2018_03_001
crossref_primary_10_1371_journal_pone_0078474
crossref_primary_10_1097_TP_0000000000000354
crossref_primary_10_26565_2617_409X_2021_8_06
crossref_primary_10_1007_s10875_020_00790_x
crossref_primary_10_1038_s41598_023_31858_4
crossref_primary_10_1371_journal_pone_0081881
crossref_primary_10_1038_cti_2015_1
crossref_primary_10_3389_fimmu_2024_1466339
crossref_primary_10_3389_fcimb_2021_605258
crossref_primary_10_7759_cureus_60329
crossref_primary_10_1016_j_biomaterials_2020_120158
crossref_primary_10_4049_jimmunol_1401513
crossref_primary_10_4103_IJO_IJO_1213_23
crossref_primary_10_1007_s40588_023_00203_8
crossref_primary_10_3390_vaccines7040217
Cites_doi 10.1017/CBO9780511545313.054
10.1371/journal.ppat.1001051
10.1111/j.1365-2141.2005.05452.x
10.1016/j.immuni.2008.02.020
10.1016/S0140-6736(64)91524-7
10.1073/pnas.59.1.94
10.1128/CMR.00044-10
10.1084/jem.187.9.1395
10.1111/1523-1747.ep12499958
10.1111/j.0105-2896.2010.00897.x
10.1093/bioinformatics/btm044
10.1086/523815
10.1086/505400
10.1089/088922201750251981
10.1086/491740
10.1016/S0140-6736(86)90531-3
10.1084/jem.20112401
10.1146/annurev.immunol.25.022106.141553
10.1371/journal.ppat.1000496
10.4049/jimmunol.173.4.2410
10.1182/blood.V98.13.3739
10.1002/ijc.2910340506
ContentType Journal Article
Copyright Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America
2014 INIST-CNRS
The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: . 2012
Copyright_xml – notice: Copyright © 2013 Oxford University Press on behalf of the Infectious Diseases Society of America
– notice: 2014 INIST-CNRS
– notice: The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: . 2012
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
7U9
H94
5PM
DOI 10.1093/infdis/jis646
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
DatabaseTitleList

MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1537-6613
EndPage 88
ExternalDocumentID PMC3523797
23100562
27110422
10_1093_infdis_jis646
41726169
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Minnesota
GeographicLocations_xml – name: Minnesota
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: P01AI35296
– fundername: NIAID NIH HHS
  grantid: P01 AI035296
– fundername: NIAID NIH HHS
  grantid: F31 AI084524
– fundername: NIAID NIH HHS
  grantid: F31AI084524
– fundername: NCI NIH HHS
  grantid: T32 CA009138
GroupedDBID ---
-DZ
-~X
..I
.2P
.I3
.XZ
.ZR
08P
0R~
123
1KJ
1TH
29K
2AX
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABBHK
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ABZBJ
ACGFO
ACGFS
ACGOD
ACHIC
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFZL
AFIYH
AFOFC
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQVQM
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
EBS
ECGQY
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IH2
IOX
IPSME
J21
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
MHKGH
MJL
ML0
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TR2
W2D
W8F
WH7
X7H
YAYTL
YKOAZ
YXANX
~91
AAYXX
CITATION
.55
.GJ
3O-
41~
AAFWJ
AAPGJ
AAWDT
ABDPE
ABSMQ
ACFRR
ACPQN
ACVCV
ACZBC
ADMTO
AEKPW
AFFNX
AFFQV
AFHKK
AFQQW
AFSHK
AGKRT
AGMDO
AHGBF
AI.
AJDVS
APJGH
AQDSO
AQKUS
AVNTJ
BZKNY
EIHJH
HQ3
HTVGU
IQODW
J5H
MBLQV
MVM
N4W
NEJ
OBFPC
O~Y
P0-
TMA
VH1
X7M
Y6R
ZE2
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T5
7U9
H94
5PM
ID FETCH-LOGICAL-c472t-f52a62186084539048401758bf3f2bca0b2e2a70f801db014781c9d391b37df63
ISSN 0022-1899
1537-6613
IngestDate Thu Aug 21 13:55:36 EDT 2025
Thu Jul 10 23:24:41 EDT 2025
Fri Jul 11 00:35:03 EDT 2025
Mon Jul 21 06:03:03 EDT 2025
Mon Jul 21 09:13:29 EDT 2025
Tue Jul 01 02:51:50 EDT 2025
Thu Apr 24 22:55:43 EDT 2025
Sun Aug 24 12:10:32 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Gammaherpesvirinae
Virus
Infection
Primary infection
Herpesviridae
Epstein Barr virus
Student
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c472t-f52a62186084539048401758bf3f2bca0b2e2a70f801db014781c9d391b37df63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Presented in part: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 18 September 2011. Abstract V494.
OpenAccessLink https://academic.oup.com/jid/article-pdf/207/1/80/16866890/jis646.pdf
PMID 23100562
PQID 1273272889
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3523797
proquest_miscellaneous_1642625665
proquest_miscellaneous_1273272889
pubmed_primary_23100562
pascalfrancis_primary_27110422
crossref_primary_10_1093_infdis_jis646
crossref_citationtrail_10_1093_infdis_jis646
jstor_primary_41726169
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-01-01
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – month: 01
  year: 2013
  text: 2013-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Oxford
PublicationPlace_xml – name: Oxford
– name: United States
PublicationTitle The Journal of infectious diseases
PublicationTitleAlternate J Infect Dis
PublicationYear 2013
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Crawford ( key 20170511122816_JIS646C18) 2006; 43
Miller ( key 20170511122816_JIS646C11) 2008; 28
Williams ( key 20170511122816_JIS646C21) 2005; 129
Melbye ( key 20170511122816_JIS646C5) 1984; 34
Hislop ( key 20170511122816_JIS646C15) 2007; 25
Hjalgrim ( key 20170511122816_JIS646C6) 2007
Castiglione ( key 20170511122816_JIS646C23) 2007; 23
Naher ( key 20170511122816_JIS646C19) 1992; 98
Callan ( key 20170511122816_JIS646C14) 1998; 187
Silins ( key 20170511122816_JIS646C7) 2001; 98
Hadinoto ( key 20170511122816_JIS646C24) 2009; 5
Henle ( key 20170511122816_JIS646C2) 1968; 59
Balfour ( key 20170511122816_JIS646C8) 2005; 192
Sandalova ( key 20170511122816_JIS646C13) 2010; 6
Odumade ( key 20170511122816_JIS646C17) 2011; 24
de-The ( key 20170511122816_JIS646C3) 1975; 11
Doisne ( key 20170511122816_JIS646C12) 2004; 173
Welsh ( key 20170511122816_JIS646C22) 2010; 235
Balfour ( key 20170511122816_JIS646C9) 2007; 196
Epstein ( key 20170511122816_JIS646C1) 1964; 1
Sixbey ( key 20170511122816_JIS646C20) 1986; 2
Riddell ( key 20170511122816_JIS646C16) 2001; 17
Henle ( key 20170511122816_JIS646C4) 1967; 27
Odumade ( key 20170511122816_JIS646C10) 2012; 209
15813855 - Br J Haematol. 2005 Apr;129(2):266-74
22393125 - J Exp Med. 2012 Mar 12;209(3):471-8
14107961 - Lancet. 1964 Mar 28;1(7335):702-3
11739180 - Blood. 2001 Dec 15;98(13):3739-44
18468462 - Immunity. 2008 May;28(5):710-22
4295480 - Cancer Res. 1967 Dec;27(12):2442-6
1314867 - J Invest Dermatol. 1992 May;98(5):791-3
16804839 - Clin Infect Dis. 2006 Aug 1;43(3):276-82
23100564 - J Infect Dis. 2013 Jan 1;207(1):6-8
5242134 - Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101
J Infect Dis. 2013 Jun 15;207(12):1940
18190249 - J Infect Dis. 2007 Dec 15;196(12):1724-6
20808900 - PLoS Pathog. 2010;6(8):e1001051
20536568 - Immunol Rev. 2010 May;235(1):244-66
16206064 - J Infect Dis. 2005 Nov 1;192(9):1505-12
9565632 - J Exp Med. 1998 May 4;187(9):1395-402
2877273 - Lancet. 1986 Nov 15;2(8516):1122-4
21233512 - Clin Microbiol Rev. 2011 Jan;24(1):193-209
17341499 - Bioinformatics. 2007 Jun 1;23(11):1371-7
191375 - IARC Sci Publ. 1975;(11 Pt 2):3-16
6094363 - Int J Cancer. 1984 Nov 15;34(5):619-23
11429120 - AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):789-97
15294954 - J Immunol. 2004 Aug 15;173(4):2410-8
17378764 - Annu Rev Immunol. 2007;25:587-617
19578433 - PLoS Pathog. 2009 Jul;5(7):e1000496
References_xml – start-page: 929
  volume-title: Human herpesviruses: biology, therapy, and immunoprophylaxis
  year: 2007
  ident: key 20170511122816_JIS646C6
  article-title: The epidemiology of EBV and its association with malignant disease
  doi: 10.1017/CBO9780511545313.054
– volume: 6
  start-page: e1001051
  year: 2010
  ident: key 20170511122816_JIS646C13
  article-title: Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1001051
– volume: 129
  start-page: 266
  year: 2005
  ident: key 20170511122816_JIS646C21
  article-title: The immune response to primary EBV infection: a role for natural killer cells
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2005.05452.x
– volume: 28
  start-page: 710
  year: 2008
  ident: key 20170511122816_JIS646C11
  article-title: Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines
  publication-title: Immunity
  doi: 10.1016/j.immuni.2008.02.020
– volume: 1
  start-page: 702
  year: 1964
  ident: key 20170511122816_JIS646C1
  article-title: Virus particles in cultured lymphoblasts from Burkitt's lymphoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(64)91524-7
– volume: 59
  start-page: 94
  year: 1968
  ident: key 20170511122816_JIS646C2
  article-title: Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.59.1.94
– volume: 24
  start-page: 193
  year: 2011
  ident: key 20170511122816_JIS646C17
  article-title: Progress and problems in understanding and managing primary Epstein-Barr virus infections
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.00044-10
– volume: 187
  start-page: 1395
  year: 1998
  ident: key 20170511122816_JIS646C14
  article-title: Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo
  publication-title: J Exp Med
  doi: 10.1084/jem.187.9.1395
– volume: 98
  start-page: 791
  year: 1992
  ident: key 20170511122816_JIS646C19
  article-title: Subclinical Epstein-Barr virus infection of both the male and female genital tract–indication for sexual transmission
  publication-title: J Invest.Dermatol
  doi: 10.1111/1523-1747.ep12499958
– volume: 235
  start-page: 244
  year: 2010
  ident: key 20170511122816_JIS646C22
  article-title: Heterologous immunity between viruses
  publication-title: Immunol Rev
  doi: 10.1111/j.0105-2896.2010.00897.x
– volume: 23
  start-page: 1371
  year: 2007
  ident: key 20170511122816_JIS646C23
  article-title: Simulating Epstein-Barr virus infection with C-ImmSim
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btm044
– volume: 196
  start-page: 1724
  year: 2007
  ident: key 20170511122816_JIS646C9
  article-title: Epstein-Barr virus vaccine for the prevention of infectious mononucleosis—and what else?
  publication-title: J Infect Dis
  doi: 10.1086/523815
– volume: 27
  start-page: 2442
  year: 1967
  ident: key 20170511122816_JIS646C4
  article-title: Immunofluorescence, interference, and complement fixation technics in the detection of the herpes-type virus in Burkitt tumor cell lines
  publication-title: Cancer Res
– volume: 43
  start-page: 276
  year: 2006
  ident: key 20170511122816_JIS646C18
  article-title: A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis
  publication-title: Clin Infect Dis
  doi: 10.1086/505400
– volume: 17
  start-page: 789
  year: 2001
  ident: key 20170511122816_JIS646C16
  article-title: A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease
  publication-title: AIDS Res Hum Retroviruses
  doi: 10.1089/088922201750251981
– volume: 192
  start-page: 1505
  year: 2005
  ident: key 20170511122816_JIS646C8
  article-title: A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis
  publication-title: J Infect Dis
  doi: 10.1086/491740
– volume: 2
  start-page: 1122
  year: 1986
  ident: key 20170511122816_JIS646C20
  article-title: A second site for Epstein-Barr virus shedding: the uterine cervix
  publication-title: Lancet
  doi: 10.1016/S0140-6736(86)90531-3
– volume: 11
  start-page: 113
  year: 1975
  ident: key 20170511122816_JIS646C3
  article-title: Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review
  publication-title: IARC Sci Publ
– volume: 209
  start-page: 471
  year: 2012
  ident: key 20170511122816_JIS646C10
  article-title: Primary Epstein-Barr virus infection does not erode preexisting CD8 T cell memory in humans
  publication-title: J Exp Med
  doi: 10.1084/jem.20112401
– volume: 25
  start-page: 587
  year: 2007
  ident: key 20170511122816_JIS646C15
  article-title: Cellular responses to viral infection in humans: lessons from Epstein-Barr virus
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.25.022106.141553
– volume: 5
  start-page: e1000496
  year: 2009
  ident: key 20170511122816_JIS646C24
  article-title: The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1000496
– volume: 173
  start-page: 2410
  year: 2004
  ident: key 20170511122816_JIS646C12
  article-title: CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection
  publication-title: J Immunol
  doi: 10.4049/jimmunol.173.4.2410
– volume: 98
  start-page: 3739
  year: 2001
  ident: key 20170511122816_JIS646C7
  article-title: Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load
  publication-title: Blood
  doi: 10.1182/blood.V98.13.3739
– volume: 34
  start-page: 619
  year: 1984
  ident: key 20170511122816_JIS646C5
  article-title: Early primary infection and high Epstein-Barr virus antibody titers in Greenland Eskimos at high risk for nasopharyngeal carcinoma
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910340506
– reference: 9565632 - J Exp Med. 1998 May 4;187(9):1395-402
– reference: 2877273 - Lancet. 1986 Nov 15;2(8516):1122-4
– reference: 15294954 - J Immunol. 2004 Aug 15;173(4):2410-8
– reference: 6094363 - Int J Cancer. 1984 Nov 15;34(5):619-23
– reference: 11739180 - Blood. 2001 Dec 15;98(13):3739-44
– reference: 16206064 - J Infect Dis. 2005 Nov 1;192(9):1505-12
– reference: 191375 - IARC Sci Publ. 1975;(11 Pt 2):3-16
– reference: 1314867 - J Invest Dermatol. 1992 May;98(5):791-3
– reference: 16804839 - Clin Infect Dis. 2006 Aug 1;43(3):276-82
– reference: 19578433 - PLoS Pathog. 2009 Jul;5(7):e1000496
– reference: 17378764 - Annu Rev Immunol. 2007;25:587-617
– reference: 20808900 - PLoS Pathog. 2010;6(8):e1001051
– reference: 11429120 - AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):789-97
– reference: 21233512 - Clin Microbiol Rev. 2011 Jan;24(1):193-209
– reference: 22393125 - J Exp Med. 2012 Mar 12;209(3):471-8
– reference: 14107961 - Lancet. 1964 Mar 28;1(7335):702-3
– reference: - J Infect Dis. 2013 Jun 15;207(12):1940
– reference: 23100564 - J Infect Dis. 2013 Jan 1;207(1):6-8
– reference: 18190249 - J Infect Dis. 2007 Dec 15;196(12):1724-6
– reference: 18468462 - Immunity. 2008 May;28(5):710-22
– reference: 17341499 - Bioinformatics. 2007 Jun 1;23(11):1371-7
– reference: 15813855 - Br J Haematol. 2005 Apr;129(2):266-74
– reference: 20536568 - Immunol Rev. 2010 May;235(1):244-66
– reference: 4295480 - Cancer Res. 1967 Dec;27(12):2442-6
– reference: 5242134 - Proc Natl Acad Sci U S A. 1968 Jan;59(1):94-101
SSID ssj0004367
Score 2.5225518
Snippet Background. University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV)...
University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein-Barr virus (EBV) infection and...
Background.  University students were studied prospectively to determine the incidence of and risk factors for acquisition of primary Epstein–Barr virus (EBV)...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
jstor
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 80
SubjectTerms Antibodies
Antibodies, Viral - blood
Biological and medical sciences
Blood
CD8-Positive T-Lymphocytes - immunology
Cytokines - blood
Diseases
DNA, Viral - blood
Epstein Barr virus infections
Epstein-Barr virus
Female
Fundamental and applied biological sciences. Psychology
Herpesvirus 4, Human - genetics
Herpesvirus 4, Human - immunology
Herpesvirus 4, Human - isolation & purification
Humans
Incidence
Infections
Infectious diseases
Infectious Mononucleosis - epidemiology
Infectious Mononucleosis - immunology
Infectious Mononucleosis - transmission
Infectious Mononucleosis - virology
Kaplan-Meier Estimate
Killer Cells, Natural - immunology
Lymphocytosis - immunology
Major and Brief Reports
Male
Medical sciences
Microbiology
Minnesota - epidemiology
Miscellaneous
Natural killer cells
Prospective Studies
Risk Factors
Sentinel Surveillance
Severity of Illness Index
Students
Symptomatology
T lymphocytes
Universities
Viral Load
Viremia
Virology
Viruses
Young Adult
Title Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein-Barr Virus Infection in University Students
URI https://www.jstor.org/stable/41726169
https://www.ncbi.nlm.nih.gov/pubmed/23100562
https://www.proquest.com/docview/1273272889
https://www.proquest.com/docview/1642625665
https://pubmed.ncbi.nlm.nih.gov/PMC3523797
Volume 207
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfKEIgXBINBBkxGQrys2Ro7iZPHjbXaYFuR1oq-RUmcaEVdtrXNA3wQvgvfjnPOcVJU0OAlqlz_aXo_23f27-4IeZfAuigDKe1YURtdyR078bLUlqnMw9wDFYIpB-ezc_947H6ceJNO52eLtVQuk730-1q_kv-RKpSBXJWX7D9I1nQKBfAZ5AtPkDA87yTjQ-NjX9FVp3NcyWpG5ony_cCi3YHOq1OLA_TML-oI9iC9LafI20IWZwb_gqZpfNaRKPo3C5UT0z6M53M1SrmAZQU5XBVPskXuuMBQmYu2ztt4n-kAFdgUetG3Q81JfTzLoSJuhwWMbO6xhrK80hGCh7NSKrqagd5FenlVedUbjv7usMERwBwz0mfwtkftQw6VcMIccjROB06AuZT2snqtFjaoF7y9mDPMobuCWlyaMWFUvckHa7cPDK0FRVIFeBh8nS58d02g7vNhNBifnkaj_mR0j9xnYKGo5BlHJ58al1zuizpQvfrdOrwrDLCP3e9j5yvqEDJiFT03XsAMzTG1yjrb53cKb0snGj0hj7VQ6QEi8ynpZMUmeYDpTb9tkodnmrjxjPxooNqlBqhdCpCjLZhSDVPawJQqmNIWTKs2NUzpdU41TGkbprSCKTUwpdOCNjClNUyfk_GgP_pwbOuUIHbqCra0c4_Fvkqj1gtcj4ew_biwpXhBkvOcJWncS1jGYtHLQfGSCZj_InDSUPLQSbiQuc-3yEZxXWQvCeWuauByKUArBy03DkXGe2mgAuiJMIgt0q0lE6U6Xr5K2zKLkLfBIxRkhIK0yHtT_Qbf-08Vtyoxm1ou2BC-44cW2VmRu6nABOjoLmMWeVsDIYJNQN3sxUUG0zVywAhhggVB-Jc6vko-AdabZ5EXCJ5mBHXNB5aQRcQKrEwFFYR-9ZtielkFowcDjotQbN9h3FfkUTO3X5ON5bzM3oBKv0x2qsnzC5JzAfQ
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Behavioral%2C+Virologic%2C+and+Immunologic+Factors+Associated+With+Acquisition+and+Severity+of+Primary+Epstein-Barr+Virus+Infection+in+University+Students&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Balfour%2C+Henry+H&rft.au=Odumade%2C+Oludare+A&rft.au=Schmeling%2C+David+O&rft.au=Mullan%2C+Beth+D&rft.date=2013-01-01&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=207&rft.issue=1&rft.spage=80&rft.epage=88&rft_id=info:doi/10.1093%2Finfdis%2Fjis646&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon